老年睡眠呼吸暂停患者的气道正压治疗、死亡率与心血管风险
这项回顾性临床队列研究纳入2011—2020年美国中部多州Medicare按服务收费索赔数据中至少2次OSA诊断记录的888 835例老年受益人,中位随访3.1年。以PAP索赔证据定义启动与利用度,采用逆概率治疗加权双稳健Cox模型估计效应。启动PAP者(290 015例,32.6%)全因死亡率显著更低(HR 0.53;95%CI 0.52-0.54),MACE发生率风险更低(HR 0.90;95%CI 0.89-0.91);PAP年索赔量更高四分位与死亡率和MACE风险逐步降低相关。作者认为结果可能为评估OSA治疗对减少老年人心血管风险和死亡率重要性的试验提供信息。
要点
- 在888 835例老年OSA受益人(中位年龄73岁)中,有PAP启动证据者占32.6%,其全因死亡率显著更低(HR 0.53;95%CI 0.52-0.54)。
- PAP启动与MACE(心肌梗死、心力衰竭、卒中或冠状动脉血运重建的复合终点)发生率风险更低相关(HR 0.90;95%CI 0.89-0.91)。
- PAP年索赔量更高四分位与死亡率逐步降低相关:Q2 HR 0.84(95%CI 0.81-0.87)、Q3 HR 0.76(95%CI 0.74-0.79)、Q4 HR 0.74(95%CI 0.72-0.77)。
- PAP年索赔量更高四分位与MACE发生率风险逐步降低相关:Q2 HR 0.92(95%CI 0.89-0.95)、Q3 HR 0.89(95%CI 0.86-0.91)、Q4 HR 0.87(95%CI 0.85-0.90)。
- 作者认为结果可能为评估OSA治疗对减少老年人心血管风险和死亡率重要性的试验提供信息。
适用人群与场景
- 来自美国中部多州、全州范围、多年(2011-2020年)Medicare按服务收费索赔数据中,有2次及以上不同OSA索赔记录的Medicare受益人;共888 835例,中位(IQR)年龄73(69-78)岁,女性390 598例(43.9%),亚裔8115例(0.9%)、黑人47 122例(5.3%)、白人760 324例(85.5%);中位(IQR)随访3.1(1.5-5.1)年,随访至死亡或2020年12月31日删失。
研究设计与关键结果
- 研究类型为回顾性临床队列研究,基于2011-2020年Medicare按服务收费索赔数据,纳入888 835例有2次及以上不同OSA索赔的受益人,随访至死亡或2020年12月31日删失,分析于2021年12月至2023年12月进行。
- 暴露为OSA诊断后PAP索赔所提示的PAP启动与利用度;主要终点为全因死亡率和MACE(心肌梗死、心力衰竭、卒中或冠状动脉血运重建的复合终点)。
- 采用逆概率治疗权重的双稳健Cox比例风险模型估计效应量,控制社会人口学和临床因素。
- 有PAP启动证据者290 015例(32.6%),其全因死亡率显著更低(HR 0.53;95%CI 0.52-0.54),MACE发生率风险更低(HR 0.90;95%CI 0.89-0.91)。
- PAP年索赔量更高四分位与死亡率逐步降低相关:Q2 HR 0.84(95%CI 0.81-0.87)、Q3 HR 0.76(95%CI 0.74-0.79)、Q4 HR 0.74(95%CI 0.72-0.77)。
- PAP年索赔量更高四分位与MACE发生率风险逐步降低相关:Q2 HR 0.92(95%CI 0.89-0.95)、Q3 HR 0.89(95%CI 0.86-0.91)、Q4 HR 0.87(95%CI 0.85-0.90)。
证据类型、等级与局限
- 证据类型:回顾性临床队列研究;原文未报告证据等级或推荐强度。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在老年OSA患者中PAP利用与较低全因死亡率和MACE发生率相关,结果可能为评估OSA治疗对减少老年人心血管风险和死亡率重要性的试验提供信息。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Positive airway pressure (PAP) is the first-line treatment for obstructive sleep apnea (OSA), but evidence on its beneficial effect on major adverse cardiovascular events (MACE) and mortality prevention is limited.
OBJECTIVE: To determine whether PAP initiation and utilization are associated with lower mortality and incidence of MACE among older adults with OSA living in the central US.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective clinical cohort study included Medicare beneficiaries with 2 or more distinct OSA claims identified from multistate, statewide, multiyear (2011-2020) Medicare fee-for-service claims data. Individuals were followed up until death or censoring on December 31, 2020. Analyses were performed between December 2021 and December 2023.
EXPOSURES: Evidence of PAP initiation and utilization based on PAP claims after OSA diagnosis.
MAIN OUTCOMES AND MEASURES: All-cause mortality and MACE, defined as a composite of myocardial infarction, heart failure, stroke, or coronary revascularization. Doubly robust Cox proportional hazards models with inverse probability of treatment weights were used to estimate treatment effect sizes controlling for sociodemographic and clinical factors.
RESULTS: Among 888 835 beneficiaries with OSA included in the analyses (median [IQR] age, 73 [69-78] years; 390 598 women [43.9%]; 8115 Asian [0.9%], 47 122 Black [5.3%], and 760 324 White [85.5%] participants; median [IQR] follow-up, 3.1 [1.5-5.1] years), those with evidence of PAP initiation (290 015 [32.6%]) had significantly lower all-cause mortality (hazard ratio [HR], 0.53; 95% CI, 0.52-0.54) and MACE incidence risk (HR, 0.90; 95% CI, 0.89-0.91). Higher quartiles (Q) of annual PAP claims were progressively associated with lower mortality (Q2 HR, 0.84; 95% CI, 0.81-0.87; Q3 HR, 0.76; 95% CI, 0.74-0.79; Q4 HR, 0.74; 95% CI, 0.72-0.77) and MACE incidence risk (Q2 HR, 0.92; 95% CI, 0.89-0.95; Q3 HR, 0.89; 95% CI, 0.86-0.91; Q4 HR, 0.87; 95% CI, 0.85-0.90).
CONCLUSIONS AND RELEVANCE: In this cohort study of Medicare beneficiaries with OSA, PAP utilization was associated with lower all-cause mortality and MACE incidence. Results might inform trials assessing the importance of OSA therapy toward minimizing cardiovascular risk and mortality in older adults.
参考来源
- Mazzotti DR, Waitman LR, Miller J, et al. Positive Airway Pressure, Mortality, and Cardiovascular Risk in Older Adults With Sleep Apnea. JAMA Netw Open. 2024. PMID: 39259540. doi:10.1001/jamanetworkopen.2024.32468
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。